Investigating the Therapeutic Potential for Selective Late INa Blockers in the Management of Type 2 Long QT Syndrome

Grants and Contracts Details

StatusFinished
Effective start/end date2/17/141/30/16

Funding

  • Gilead Sciences Inc: $112,500.00